Molecular genetics of medullary thyroid carcinoma: the quest for novel therapeutic targets.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Journal of Molecular Endocrinology

• Publication date

  2009-10-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1677/JME-09-0024PMID 19383830
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Absence of H- and K-ras oncogene mutations in sporadic medullary thyroid carcinoma.

  2012cited by this paper
• Pathology and Genetics

  2010cited by this paper
• Is NF-κB a good target for cancer therapy? Hopes and pitfalls

  2009cited by this paper
• Proteomics study of medullary thyroid carcinomas expressing RET germ‐line mutations: Identification of new signaling elements

  2009cited by this paper
• P18 is a tumor suppressor gene involved in human medullary thyroid carcinoma and pheochromocytoma development

  2009cited by this paper
• RET/PTC1-driven neoplastic transformation and proinvasive phenotype of human thyrocytes involve Met induction and beta-catenin nuclear translocation.

  2009cited by this paper
• The beta-catenin axis integrates multiple signals downstream from RET/papillary thyroid carcinoma leading to cell proliferation.

  2009cited by this paper
• BRAF and K-RAS mutation in a Greek papillary and medullary thyroid carcinoma cohort.

  2008cited by this paper
• Tenets of PTEN tumor suppression.

  2008influential reference
• Analysis of Ret knockin mice reveals a critical role for IKKs, but not PI 3-K, in neurotrophic factor-induced survival of sympathetic neurons

  2008cited by this paper
• Synergistic effect of oncogenic RET and loss of p18 on medullary thyroid carcinoma development.

  2008cited by this paper
• RET/PTC-induced cell growth is mediated in part by epidermal growth factor receptor (EGFR) activation: evidence for molecular and functional interactions between RET and EGFR.

  2008cited by this paper
• Dysregulation of the phosphatidylinositol 3-kinase pathway in thyroid neoplasia.

  2008cited by this paper
• A novel RET kinase-beta-catenin signaling pathway contributes to tumorigenesis in thyroid carcinoma.

  2008cited by this paper
• Nuclear factor-kappaB activation is associated with somatic and germ line RET mutations in medullary thyroid carcinoma.

  2008cited by this paper
• Akt-dependent regulation of NF-{kappa}B is controlled by mTOR and Raptor in association with IKK.

  2008cited by this paper
• Receptor tyrosine kinase inhibitors in thyroid cancer.

  2008cited by this paper
• PI3K pathway alterations in cancer: variations on a theme

  2008influential reference
• Myeloproliferative disorders.

  2008cited by this paper
• High resolution array-comparative genomic hybridization profiling reveals deoxyribonucleic acid copy number alterations associated with medullary thyroid carcinoma.

  2008cited by this paper
• Intragenic mutations in thyroid cancer.

  2008cited by this paper
• Systematic analyses of the cancer genome: lessons learned from sequencing most of the annotated human protein-coding genes

  2008influential reference
• Roles of induced expression of MAPK phosphatase-2 in tumor development in RET-MEN2A transgenic mice

  2008cited by this paper
• New therapeutic approaches to treat medullary thyroid carcinoma

  2008cited by this paper
• Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study.

  2008cited by this paper
• Therapeutic strategies for inhibiting oncogenic BRAF signaling.

  2008cited by this paper
• The von Hippel–Lindau tumour suppressor protein: O2 sensing and cancer

  2008cited by this paper
• Early clinical studies of novel therapies for thyroid cancers.

  2008cited by this paper
• A module of negative feedback regulators defines growth factor signaling

  2007cited by this paper
• Ras/ERK1/2-mediated STAT3 Ser727 Phosphorylation by Familial Medullary Thyroid Carcinoma-associated RET Mutants Induces Full Activation of STAT3 and Is Required for c-fos Promoter Activation, Cell Mitogenicity, and Transformation*

  2007cited by this paper
• Simultaneous downregulation of CDK inhibitors p18Ink4c and p27Kip1 is required for MEN2A-RET-mediated mitogenesis

  2007cited by this paper
• Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1–like phenotype

  2007cited by this paper
• Cancer phenomics: RET and PTEN as illustrative models

  2007influential reference
• RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center.

  2007cited by this paper
• The Genomic Landscapes of Human Breast and Colorectal Cancers

  2007cited by this paper
• Genotype-Phenotype Based Surgical Concept of Hereditary Medullary Thyroid Carcinoma

  2007influential reference
• NGF augments the autophosphorylation of Ret via inhibition of ubiquitin‐dependent degradation

  2007cited by this paper
• Hyperactive Ras in developmental disorders and cancer

  2007influential reference
• A hierarchical NGF signaling cascade controls Ret-dependent and Ret-independent events during development of nonpeptidergic DRG neurons.

  2007cited by this paper
• Sprouty2 regulates growth and differentiation of human neuroblastoma cells through RET tyrosine kinase

  2007cited by this paper
• Association study of 69 genes in the ret pathway identifies low-penetrance loci in sporadic medullary thyroid carcinoma.

  2007cited by this paper
• Regulation of MAP kinases by MAP kinase phosphatases.

  2007cited by this paper
• Nras loss induces metastatic conversion of Rb1-deficient neuroendocrine thyroid tumor

  2006cited by this paper
• Gene expression in human thyrocytes and autonomous adenomas reveals suppression of negative feedbacks in tumorigenesis.

  2006cited by this paper
• Ablation of persephin receptor glial cell line-derived neurotrophic factor family receptor alpha4 impairs thyroid calcitonin production in young mice.

  2006cited by this paper
• Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro.

  2006cited by this paper
• Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans

  2006cited by this paper
• RET receptor signaling: Dysfunction in thyroid cancer and Hirschsprung's disease

  2006cited by this paper
• p18 Ink4c and Pten constrain a positive regulatory loop between cell growth and cell cycle control.

  2006influential reference
• Apoptosis-mediated medullary thyroid cancer growth suppression by the PI3K inhibitor LY294002.

  2006cited by this paper
• Epidermal growth factor receptor as a therapeutic target in human thyroid carcinoma: mutational and functional analysis.

  2006cited by this paper
• Sprouty and cancer: the first terms report.

  2006cited by this paper
• Balancing cell adhesion and Wnt signaling, the key role of beta-catenin.

  2006cited by this paper
• Somatic VHL gene alterations in MEN2-associated medullary thyroid carcinoma

  2006cited by this paper
• The myeloproliferative disorders.

  2006cited by this paper
• The receptor-type protein tyrosine phosphatase J antagonizes the biochemical and biological effects of RET-derived oncoproteins.

  2006cited by this paper
• Polymorphisms in RET and its coreceptors and ligands as genetic modifiers of multiple endocrine neoplasia type 2A.

  2006cited by this paper
• Structure and Chemical Inhibition of the RET Tyrosine Kinase Domain*

  2006cited by this paper
• Inactivation of conditional Rb by Villin-Cre leads to aggressive tumors outside the gastrointestinal tract.

  2006cited by this paper
• Critical and distinct roles for key RET tyrosine docking sites in renal development.

  2006cited by this paper
• Targeted mutation of serine 697 in the Ret tyrosine kinase causes migration defect of enteric neural crest cells

  2006cited by this paper
• Oncogenic rearrangements of the NTRK1/NGF receptor.

  2006cited by this paper
• CpG Island Methylation of Tumor-Related Promoters Occurs Preferentially in Undifferentiated Carcinoma

  2006cited by this paper
• Drug Insight: small-molecule inhibitors of protein kinases in the treatment of thyroid cancer

  2006influential reference
• Molecular genetic alterations of FHIT and p53 genes in benign and malignant thyroid gland lesions.

  2006cited by this paper
• Overexpression of the NOTCH1 Intracellular Domain Inhibits Cell Proliferation and Alters the Neuroendocrine Phenotype of Medullary Thyroid Cancer Cells*

  2006cited by this paper
• Pathogenetic mechanisms in thyroid follicular-cell neoplasia

  2006cited by this paper
• Activation of the Erk8 Mitogen-activated Protein (MAP) Kinase by RET/PTC3, a Constitutively Active Form of the RET Proto-oncogene*

  2006cited by this paper
• p18Ink4c and Pten Constrain a Positive Regulatory Loop between Cell Growth and Cell Cycle Control

  2006cited by this paper
• Balancing cell adhesion and Wnt signaling, the key role of β-catenin

  2006cited by this paper
• Polymorphisms in the initiators of RET (rearranged during transfection) signaling pathway and susceptibility to sporadic medullary thyroid carcinoma.

  2005cited by this paper
• Sprouty1 is a critical regulator of GDNF/RET-mediated kidney induction.

  2005cited by this paper
• RET Proto-Oncogene: A Review and Update of Genotype–Phenotype Correlations in Hereditary Medullary Thyroid Cancer and Associated Endocrine Tumors

  2005cited by this paper
• SRC homology-2-containing protein tyrosine phosphatase-1 restrains cell proliferation in human medullary thyroid carcinoma.

  2005cited by this paper
• Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors.

  2005cited by this paper
• Molecular genetics of multiple endocrine neoplasia types 1 and 2

  2005influential reference
• Dual inhibition of RET and FGFR4 restrains medullary thyroid cancer cell growth.

  2005cited by this paper
• Editorial: germline variants within RET: clinical utility or scientific playtoy?

  2005cited by this paper
• Nuclear factor-kappaB.

  2005cited by this paper
• No mutations but an increased frequency of SDHx polymorphisms in patients with sporadic and familial medullary thyroid carcinoma.

  2005cited by this paper
• Loss of mammalian Sprouty2 leads to enteric neuronal hyperplasia and esophageal achalasia

  2005cited by this paper
• Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A.

  2005cited by this paper
• Medullary thyroid carcinoma arises in the absence of prolactin signaling.

  2005cited by this paper
• Succinate dehydrogenase D variants do not constitute a risk factor for developing C cell hyperplasia or sporadic medullary thyroid carcinoma.

  2005cited by this paper
• A model for GFRα4 function and a potential modifying role in multiple endocrine neoplasia 2

  2005cited by this paper
• Genetics of papillary thyroid cancer initiation: implications for therapy.

  2005cited by this paper
• A model for GFR alpha 4 function and a potential modifying role in multiple endocrine neoplasia 2.

  2005cited by this paper
• RET-familial medullary thyroid carcinoma mutants Y791F and S891A activate a Src/JAK/STAT3 pathway, independent of glial cell line-derived neurotrophic factor.

  2005cited by this paper
• BRAF mutation in thyroid cancer.

  2005cited by this paper
• The RET proto‐oncogene: A molecular therapeutic target in thyroid cancer

  2005cited by this paper
• Role of MEN2A-derived RET in maintenance and proliferation of medullary thyroid carcinoma.

  2004cited by this paper
• Evolving strategies for targeted cancer therapy--past, present, and future.

  2004cited by this paper
• Molecular Genotyping of Medullary Thyroid Carcinoma Can Predict Tumor Recurrence

  2004cited by this paper
• The Shp-1 and Shp-2, tyrosine phosphatases, are recruited on cell membrane in two distinct molecular complexes including Ret oncogenes.

  2004cited by this paper
• RET exon 11 (G691S) polymorphism is significantly more frequent in sporadic medullary thyroid carcinoma than in the general population.

  2004cited by this paper
• Tyrosine 981, a Novel Ret Autophosphorylation Site, Binds c-Src to Mediate Neuronal Survival*

  2004cited by this paper
• Molecular biology of primary hyperparathyroidism.

  2004cited by this paper
• The tor pathway: a target for cancer therapy

  2004cited by this paper
• The RAF proteins take centre stage

  2004cited by this paper
• Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors.

  2004cited by this paper

• Kinome profiling reveals pathogenic variant specific protein signalling networks in MEN2 children with Medullary Thyroid Cancer

  2025cites this paper
• A collision tumour of thyroid (papillary carcinoma + medullary carcinoma of thyroid): A rare case

  2025cites this paper
• Selpercatinib in the treatment of thyroid cancer.

  2025cites this paper
• A novel role for nonactin: interfering with G-quadruplex in RET-driven medullary thyroid cancer

  2024cites this paper
• Thyroid Cancer: A Review.

  2024cites this paper
• Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer.

  2023cites this paper
• Looking for RET alterations in thyroid cancer: clinical relevance, methodology and timing

  2023cites this paper
• Circulating miR-26b-5p and miR-451a as diagnostic biomarkers in medullary thyroid carcinoma patients

  2023cites this paper
• Faulty Metabolism: A Potential Instigator of an Aggressive Phenotype in Cdk5-dependent Medullary Thyroid Carcinoma

  2023cites this paper
• Thyroid Carcinoma, Version 2.2022

  2022cites this paper
• Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.

  2022cites this paper
• Sporadic Medullary Thyroid Carcinoma: Towards a Precision Medicine

  2022cites this paper
• Research Progress of DNA Methylation in Thyroid Cancer

  2020cites this paper
• Genetic Landscape of Somatic Mutations in a Large Cohort of Sporadic Medullary Thyroid Carcinomas Studied by Next-Generation Targeted Sequencing

  2019cites this paper
• The role of molecular genetics in the clinical management of sporadic medullary thyroid carcinoma: A systematic review

  2019cites this paper
• Identifying disease-associated genes based on artificial intelligence

  2019cites this paper
• Targeting RET-rearranged non-small-cell lung cancer: future prospects

  2019cites this paper
• Medullary Thyroid Carcinoma and Papillary Thyroid Carcinoma in the Same Patient as a Collision Tumour

  2019cites this paper
• Disease Gene Prediction by Integrating PPI Networks, Clinical RNA-Seq Data and OMIM Data

  2019cites this paper
• Integrated computational and Drosophila cancer model platform captures previously unappreciated chemicals perturbing a kinase network

  2018influential citation
• Quantitative Proteomics Analysis of Sporadic Medullary Thyroid Cancer Reveals FN1 as a Potential Novel Candidate Prognostic Biomarker.

  2018cites this paper
• Selective Ablation of Tumor Suppressors in Parafollicular C Cells Elicits Medullary Thyroid Carcinoma*

  2017cites this paper
• Modeling Human Cancers in Drosophila.

  2017cites this paper
• Animal models of medullary thyroid cancer: state of the art and view to the future.

  2017cites this paper
• Reduced Retinoblastoma Protein Expression Is Associated with Decreased Patient Survival in Medullary Thyroid Cancer

  2017cites this paper
• A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma

  2016cites this paper
• Construction of human single-chain variable fragment antibodies of medullary thyroid carcinoma and single photon emission computed tomography/computed tomography imaging in tumor-bearing nude mice.

  2016cites this paper
• Medullary Thyroid Cancer: A Case Series and Review of the Literature

  2016cites this paper
• Development and clinical application of an integrative genomic approach to personalized cancer therapy

  2016cites this paper
• Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer

  2016cites this paper
• Medullary Thyroid Cancer: A Case Series and Review of the Literature Medüller Tiroid Kanseri: Bir Olgu Serisi ve Literatürün Gözden Geçirilmesi

  2016cites this paper
• Signaling pathways in medullary thyroid carcinoma: therapeutic implications

  2016cites this paper
• Putative BRAF activating fusion in a medullary thyroid cancer

  2016influential citation
• Analysis of BRAF and RAS genetic alterations in thyroid cancer in the Greek population

  2016cites this paper
• Synergistic antitumour activity of RAF265 and ZSTK474 on human TT medullary thyroid cancer cells

  2015cites this paper
• PI3K/Akt/mTOR signaling in medullary thyroid cancer: a promising molecular target for cancer therapy

  2015cites this paper
• Identification of Driving ALK Fusion Genes and Genomic Landscape of Medullary Thyroid Cancer

  2015cites this paper
• Cabozantinib in Thyroid Cancer.

  2015cites this paper
• Identification and characterization of two novel germline RET variants associated with medullary thyroid carcinoma

  2015cites this paper
• RAS proto-oncogene in medullary thyroid carcinoma.

  2015cites this paper
• Clinicopathological Features of Rare BRAF Mutations in Korean Thyroid Cancer Patients

  2014cites this paper
• Expression pattern of carbonic anhydrase IX in Medullary thyroid carcinoma supports a role for RET-mediated activation of the HIF pathway.

  2014cites this paper
• mTOR activation in medullary thyroid carcinoma with RAS mutation.

  2014cites this paper
• Medullary Thyroid Carcinoma: a 25-Year Perspective

  2014cites this paper
• RET gene mutations (genotype and phenotype) of multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma

  2014cites this paper
• Cabozantinib for progressive metastatic medullary thyroid cancer: a review

  2014cites this paper
• Cabozantinib for progressive metastatic medullary thyroid cancer: a review

  2014cites this paper
• Cabozantinib for progressive metastatic medullary thyroid cancer: a review

  2014cites this paper
• p53 suppresses carcinoma progression by inhibiting mTOR pathway activation

  2014influential citation
• Upregulation of the PI3K/Akt Pathway in the Tumorigenesis of Canine Thyroid Carcinoma

  2014influential citation
• Medullary and Papillary Thyroid Carcinoma as a Collision Tumor: Report of Five Cases

  2014cites this paper
• Cabozantinib for progressive metastatic medullary thyroid cancer: a review

  2014cites this paper
• Pharmacokinetic evaluation of cabozantinib for the treatment of thyroid cancer

  2013cites this paper
• New Diagnostic and Therapeutic Tools for Thyroid Cancer

  2013cites this paper
• Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS.

  2013cites this paper
• Treatment directed to signalling molecules in patients with advanced differentiated thyroid cancer.

  2013influential citation
• Cellular Signaling Pathway Alterations and Potential Targeted Therapies for Medullary Thyroid Carcinoma

  2013cites this paper
• Protein kinase C: a putative new target for the control of human medullary thyroid carcinoma cell proliferation in vitro.

  2012cites this paper
• Evidence of a Low Prevalence of RAS Mutations in a Large Medullary Thyroid Cancer Series

  2012influential citation
• High‐resolution analysis of alterations in medullary thyroid carcinoma genomes

  2012cites this paper
• Human Cancer Biology Activationof themTORPathway inPrimaryMedullary Thyroid Carcinoma and Lymph Node Metastases

  2012cites this paper
• Surgical strategies in patients with medullary thyroid carcinoma.

  2012cites this paper
• Chromosome 10 and RET gene copy number alterations in hereditary and sporadic Medullary Thyroid Carcinoma.

  2012cites this paper
• Vandetanib for the Treatment of Thyroid Cancer

  2012cites this paper
• Thyroid Cancer: Molecular Genetics

  2012cites this paper
• Targeted Therapy of Thyroid Cancer

  2012cites this paper
• Activation of the mTOR Pathway in Primary Medullary Thyroid Carcinoma and Lymph Node Metastases

  2012cites this paper
• AUTHOR COPY ONLY

  2011cites this paper
• Sprouty1 is a candidate tumor suppressor gene in medullary thyroid carcinoma

  2011cites this paper
• Diagnostic and Prognostic Markers in Differentiated Thyroid Cancer

  2011cites this paper
• Medullary and papillary carcinoma of the thyroid gland occurring as a collision tumor with lymph node metastasis: A case report

  2011cites this paper
• CDKN1B V109G polymorphism a new prognostic factor in sporadic medullary thyroid carcinoma.

  2011cites this paper
• A family presenting with multiple endocrine neoplasia type 2B: A case report

  2011cites this paper
• CDKN 1 B V 109 G polymorphism a new prognostic factor in sporadic medullary thyroid carcinoma

  2011cites this paper
• Avaliação da expressão do RKIP e CD147 em carcinomas da cavidade oral

  2011cites this paper
• RET Mediated Gene Expression and Cell-Migration

  2011cites this paper
• Diagnostic and Prognostic Markers in Differentiated Thyroid Cancer

  2011cites this paper
• 1 CDKN 1 B V 109 G Polymorphism a New Prognostic Factor in Sporadic Medullary Thyroid Carcinoma

  2010cites this paper
• Medullary Carcinoma Clinical Practice Guidelines in Oncology TM

  2010cites this paper
• In search of diagnostic and prognostic markers for thyroid cancer : A proteomics approach

  2010cites this paper
• The evolving field of tyrosine kinase inhibitors in the treatment of endocrine tumors.

  2010cites this paper
• Sorafenib in metastatic MTC – a case report and minireview of the literature

  2010influential citation
• Medullary thyroid cancer: a promising model for targeted therapy.

  2010cites this paper
• Medullary carcinoma.

  2010cites this paper
• Raf-1 Kinase Inhibitory Protein Expression in Thyroid Carcinomas

  2010cites this paper
• Tyrosine kinases as molecular targets to inhibit cancer progression and metastasis.

  2010cites this paper
• Witnessing a New Era?—The Emerging Role of Targeted Drugs in the Medical Treatment of Advanced Medullary and Anaplastic Thyroid Cancer

  2010cites this paper
• The Role of BetaPIX in RET-mediated Cell Migration

  2009cites this paper
• International Medical Case Reports Journal Dovepress Sorafenib in Metastatic Mtc – a Case Report and Minireview of the Literature

  year unknowncites this paper